Cargando…

A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?

BACKGROUND: Patient decision aids (PDAs) are tools designed to facilitate decision-making. In this systematic review, we summarized existing studies on the development and evaluation of PDAs for patients with hematologic malignancies. PATIENTS AND METHODS: We followed the Preferred Reporting Items f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Janice, Abdallah, Maya, Sanapala, Chandrika, Watson, Erin, LoCastro, Marissa, Castillo, Daniel A, Richardson, Daniel, LeBlanc, Thomas W, Loh, Kah Poh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907042/
https://www.ncbi.nlm.nih.gov/pubmed/36342114
http://dx.doi.org/10.1093/oncolo/oyac231
_version_ 1784884091378728960
author Zhao, Janice
Abdallah, Maya
Sanapala, Chandrika
Watson, Erin
LoCastro, Marissa
Castillo, Daniel A
Richardson, Daniel
LeBlanc, Thomas W
Loh, Kah Poh
author_facet Zhao, Janice
Abdallah, Maya
Sanapala, Chandrika
Watson, Erin
LoCastro, Marissa
Castillo, Daniel A
Richardson, Daniel
LeBlanc, Thomas W
Loh, Kah Poh
author_sort Zhao, Janice
collection PubMed
description BACKGROUND: Patient decision aids (PDAs) are tools designed to facilitate decision-making. In this systematic review, we summarized existing studies on the development and evaluation of PDAs for patients with hematologic malignancies. PATIENTS AND METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched for articles in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. We included studies, abstracts, and clinical trial protocols available in English involving PDAs for patients age ≥18 diagnosed with a hematologic malignancy and/or their caregivers. Data were summarized using descriptive statistics. RESULTS: Of the 5281 titles/abstracts screened, 15 were included: 1 protocol, 7 abstracts, and 7 full-texts. Six were PDA developmental studies, 6 were pilot studies, and 3 were randomized trials. PDA formats included electronic with web content, videos, and/or audio, questionnaires, bedside instruments, and a combination of various formats. Average participant age ranged from 36.0 to 62.4 years. Patients and caregivers identified efficacy, adverse effects, cost, and quality of life as important decision-making factors. PDAs were associated with increased knowledge and patient satisfaction as well as decreased decisional conflict and attitudinal barriers. Research on PDAs for adult patients with hematologic malignancies and their caregivers is limited. Among the studies, PDAs appear to support patients in shared decision-making. CONCLUSION: While current literature examining the use of PDAs for adults with hematologic malignancies is limited, the positive impact of PDAs on shared decision-making and patient outcomes warrants additional research in this field.
format Online
Article
Text
id pubmed-9907042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-99070422023-02-09 A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing? Zhao, Janice Abdallah, Maya Sanapala, Chandrika Watson, Erin LoCastro, Marissa Castillo, Daniel A Richardson, Daniel LeBlanc, Thomas W Loh, Kah Poh Oncologist Hematologic Malignancies BACKGROUND: Patient decision aids (PDAs) are tools designed to facilitate decision-making. In this systematic review, we summarized existing studies on the development and evaluation of PDAs for patients with hematologic malignancies. PATIENTS AND METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched for articles in PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. We included studies, abstracts, and clinical trial protocols available in English involving PDAs for patients age ≥18 diagnosed with a hematologic malignancy and/or their caregivers. Data were summarized using descriptive statistics. RESULTS: Of the 5281 titles/abstracts screened, 15 were included: 1 protocol, 7 abstracts, and 7 full-texts. Six were PDA developmental studies, 6 were pilot studies, and 3 were randomized trials. PDA formats included electronic with web content, videos, and/or audio, questionnaires, bedside instruments, and a combination of various formats. Average participant age ranged from 36.0 to 62.4 years. Patients and caregivers identified efficacy, adverse effects, cost, and quality of life as important decision-making factors. PDAs were associated with increased knowledge and patient satisfaction as well as decreased decisional conflict and attitudinal barriers. Research on PDAs for adult patients with hematologic malignancies and their caregivers is limited. Among the studies, PDAs appear to support patients in shared decision-making. CONCLUSION: While current literature examining the use of PDAs for adults with hematologic malignancies is limited, the positive impact of PDAs on shared decision-making and patient outcomes warrants additional research in this field. Oxford University Press 2022-11-07 /pmc/articles/PMC9907042/ /pubmed/36342114 http://dx.doi.org/10.1093/oncolo/oyac231 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hematologic Malignancies
Zhao, Janice
Abdallah, Maya
Sanapala, Chandrika
Watson, Erin
LoCastro, Marissa
Castillo, Daniel A
Richardson, Daniel
LeBlanc, Thomas W
Loh, Kah Poh
A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
title A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
title_full A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
title_fullStr A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
title_full_unstemmed A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
title_short A Systematic Review of Decision Aids in Hematologic Malignancies: What Are Currently Available and What Are We Missing?
title_sort systematic review of decision aids in hematologic malignancies: what are currently available and what are we missing?
topic Hematologic Malignancies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907042/
https://www.ncbi.nlm.nih.gov/pubmed/36342114
http://dx.doi.org/10.1093/oncolo/oyac231
work_keys_str_mv AT zhaojanice asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT abdallahmaya asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT sanapalachandrika asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT watsonerin asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT locastromarissa asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT castillodaniela asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT richardsondaniel asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT leblancthomasw asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT lohkahpoh asystematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT zhaojanice systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT abdallahmaya systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT sanapalachandrika systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT watsonerin systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT locastromarissa systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT castillodaniela systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT richardsondaniel systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT leblancthomasw systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing
AT lohkahpoh systematicreviewofdecisionaidsinhematologicmalignancieswhatarecurrentlyavailableandwhatarewemissing